 Altadena, CA, July 22, 2021 GLOBE NEWSWIRE -- Lixte Biotechnology Holdings, Inc. Nasdaq:LIXTE a clinical-stage drug discovery company developing pharmacologically active drugs for improving cancer treatments, commented on pre-clinical research demonstrating that inhibition of protein phosphatase 2A PP2A with LB-100 combined with the experimental drug, vosoritide BioMarin, was even more effective than vosorotide alone in stimulating bone length and cartilage area in a mouse model of the most common form of dwarfism, achondroplasia ACH. 